Why Curaleaf Stock Was Tumbling on Tuesday
Now, it’s worth noting Stock Advisor’s total average return is 1,076% — a market-crushing outperformance compared to 184 % for the S&P 500. Don’t miss out on the latest top 10 list, available when you …
Trump weighs reclassifying cannabis: What’s at stake for weed stocks
US President Trump is reportedly considering reclassifying marijuana from the federal government’s current Schedule 1 classification. Seymour Asset Management founder, CIO, and Amplify ETFs portfolio …
Marijuana dispensary debate continues in Grove City
Grove City voted to allow up to two marijuana dispensaries within city limits about three years ago, but the city still does not have a marijuana dispensary, more than a year after recreational …
Major reforms to medical marijuana program become law
The new law will make it easier and cheaper to get a medical cannabis card by legalizing telehealth consultation with a doctor or advanced practice registered nurse, setting a formula to cap fees on …
As Trump looks at reclassifying cannabis, NH governor says state law won’t change
President Donald Trump is signaling that potential changes could be coming on cannabis at the federal level, but Gov. Kelly Ayotte said any developments in Washington wouldn’t change her outlook on …
CBD Stocks Creating Opportunities – Established (BCCI), (STG), (WEED), (ACRGF), (RLTR), (CBMJ), and Newcomer (VAPR) Lead the Charge
You would have to be living in isolation to have not picked up on the hottest marijuana derivative consumable and therapeutic center isolate CBD. CBD “Cannabidiol” is the non-psychoactive full spectrum derivative of the hemp and marijuana plant largely credited for the majority of the medical beneficial attributes associated with marijuana.
Here’s Why JAZZ Stock Is an Unconventional Cannabis Investment
Jazz Pharma is redefining cannabis investing with Epidiolex, a fast-growing FDA-approved epilepsy drug fueling its growth.
Why Curaleaf Stock Was Smoking the Market Today
Now, it’s worth noting Stock Advisor’s total average return is 1,079% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss out on the latest top 10 list, available when you …
Have Cannabis Stocks Totally Gone Up in Smoke?
Let’s dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in this space. The post Have Cannabis Stocks Totally Gone Up in Smoke?
High Hopes: Top U.S. Cannabis Stocks
Bipartisan interest in cannabis reform has renewed investor optimism. Despite the latest roadblock, three SA Quant picks remain well-positioned for legalization upside.
If You’d Invested $1,000 in Trulieve Cannabis (TCNNF) 3 Years Ago, Here’s How Much You’d Have Today
The price nose-dived by nearly 40%, and it was hardly the worst performer among its peer group.
Cannabis ETFs Light Up As Trump Eyes Marijuana Reclassification
Cannabis stocks and ETFs skyrocketed after Trump hinted at reclassifying marijuana. Tilray surged 35% in 2 days. Other top performers included Trulieve, Tilray, Curaleaf, and Canopy Growth. This shift …
Trump revives weed industry’s long-shot hopes — and gives local cannabis players a lift
Tom Haren, the chair of the cannabis division at Cleveland-based Frantz Ward LLP, said rescheduling could result in a new construction boom for the Ohio recreational marijuana market, which is still …
Trump revives weed industry’s long-shot hopes — and gives cannabis players a lift
If marijuana is no longer considered a Schedule I controlled substance, companies that sell weed in legal markets such as Michigan will see a big improvement to their financials. Currently, cannabis …
Tilray Brands: Is TLRY Stock The Next Big Thing?
Tilray Brands is a speculative investment with a potential for high rewards driven by prospective regulatory changes. The chance of the U.S. government reclassifying cannabis to Schedule III, …
Recent Comments